Nonapeptide-1: complete guide

Nonapeptide-1 is a synthetic cosmetic peptide that matches an alpha-MSH receptor blocker first described in 1994. This guide covers its structure, research and status.

Complete guide5 min read

Key takeaway

PubChem lists nonapeptide-1 at 1,206.5 g/mol, with two D-amino acids in its chain. In the 1994 laboratory screen, it blocked the α-MSH receptor with an IC50 of 11 nM. The EU CosIng database lists two cosmetic functions: hair conditioning and skin conditioning.

At a glance

Article typeComplete guide
Regulatory statusCosmetic / topical“Nonapeptide-1 is a cosmetic ingredient, not an FDA-approved drug.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited4 in this article · 4 across 1 article on Nonapeptide-1
Related productsCopper peptides and melanocortin fragments

Nonapeptide-1 is a synthetic nine-amino-acid peptide used as a cosmetic ingredient. It matches a peptide first described in 1994 as a blocker of the receptor for alpha-melanocyte-stimulating hormone (α-MSH). This guide covers its structure, mechanism, research and regulatory status. Sources were checked on November 17, 2026.

Quick answer: Nonapeptide-1 is a lab-made analog of part of α-MSH, the hormone that signals pigment cells. In a 1994 cell-based screen it was the most potent α-MSH antagonist found. Human evidence is limited to one small pilot study of a multi-ingredient product. It is a cosmetic ingredient, not a drug, and we found no Cosmetic Ingredient Review safety assessment for it.

Vitrapep does not sell nonapeptide-1; this page is a reference summary of published research and regulatory information.

What is nonapeptide-1?

Nonapeptide-1 is an INCI name, the standard name used on cosmetic ingredient lists. CosIng, the EU cosmetic ingredient database, calls it “a synthetic nonapeptide derived from arginine, lysine, methionine, phenylalanine, proline, tryptophan and valine” (CosIng, 2026). “Nona” means nine.

PubChem gives the sequence as Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2. It lists the formula as C61H87N15O9S and the molecular weight as 1,206.5 g/mol (PubChem CID 10418849). The “D” marks two mirror-image amino acids, D-phenylalanine and D-tryptophan. The chain ends in an amide.

PubChem also lists the name (Met5,Pro6,D-Phe7,D-Trp9,Phe10)-α-MSH (5-13). That label means it is a modified copy of positions 5 to 13 of α-MSH. Our peptide hormones guide explains how hormone fragments become research peptides.

PubChem lists Melanostatine 5 among the synonyms. We could not confirm the trade-name owner from a manufacturer source.

Table 1

Nonapeptide-1: key facts

Fact Detail
INCI name Nonapeptide-1
Structure type Linear synthetic peptide; nine amino acids, two in D form; amide end; α-MSH (5-13) analog
Sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2
Molecular formula C61H87N15O9S
Molecular weight 1,206.5 g/mol
Main cosmetic function (CosIng) Hair conditioning; skin conditioning
Trade name(s) Melanostatine 5 (PubChem synonym; owner not confirmed)

How does nonapeptide-1 work?

The key study is a 1994 paper in the Journal of Biological Chemistry. Researchers built a library of 31,360 peptides based on α-MSH positions 5 to 13 and screened about 40% of it. They looked for peptides that block the α-MSH receptor in cultured cells (Jayawickreme et al., 1994).

The most potent antagonist was Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2, the nonapeptide-1 sequence. Its IC50 was 11 ± 7 nM, a measure of how little peptide halves the hormone’s effect. The authors found that D-Trp at position 5 and Phe at position 6 “were crucial to its antagonistic properties.”

As its name says, α-MSH stimulates melanocytes, the skin’s pigment cells. An antagonist sits on the receptor without switching it on, so the hormone cannot act. This is laboratory evidence. It does not show what happens in human skin, or whether the peptide reaches the pigment cells.

What is nonapeptide-1 used for?

CosIng lists two cosmetic functions: hair conditioning and skin conditioning. A conditioning agent helps keep hair or skin in good condition. The CosIng record links no annex of the EU Cosmetics Regulation and no scientific committee opinion to this ingredient.

A 2024 study describes nonapeptide-1 as having “melanin transfer interference properties” (Huang et al., 2024). Melanin is the skin’s main pigment. For the wider field, see our peptides in skincare overview and our review of glutathione skin-lightening evidence.

What does the research show?

Jayawickreme 1994 (in vitro). The library screen above identified the nonapeptide-1 sequence as the most potent α-MSH antagonist among those tested, with an IC50 of 11 nM.

Huang 2024 (in vitro and animal). Researchers attached nonapeptide-1 to silica nanoparticles loaded with EGCG, a green tea polyphenol. Compared with free EGCG, the particles inhibited melanin 5.22 times as much and the enzyme tyrosinase 1.57 times as much. The work used cell and animal models. One affiliation is a cosmetics company, and Chinese public agencies funded the study (Huang et al., 2024). The design does not isolate nonapeptide-1.

Chatterjee 2021 (human pilot trial). This double-blind trial enrolled 46 people with melasma, 23 per group, after an initial treatment phase. One group used a product combining phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen. The other used sunscreen alone.

The combination group improved on a melasma severity score and a melanin index. The difference from the sunscreen group was not statistically significant (Chatterjee et al., 2021). The authors still judged the combination more effective at keeping remission. With several actives, the trial cannot show what nonapeptide-1 contributed.

What safety data exist?

We found no Cosmetic Ingredient Review (CIR) safety assessment for nonapeptide-1. CIR’s quick reference table, September 2020 edition, does not list it (CIR, 2020). Searches of the CIR website and PubMed found no later report. CosIng links no opinion from the EU Scientific Committee on Consumer Safety (SCCS).

The Chatterjee trial named safety as an aim, but its abstract reports no safety results. A 2026 review argues that safety review of cosmetic peptides “must also evolve” (Bjerke et al., 2026). Five of its six authors work for Procter & Gamble.

What is nonapeptide-1’s regulatory status, and how is it used in research?

Nonapeptide-1 is a cosmetic ingredient, not an FDA-approved drug. FDA states that cosmetic products and ingredients, except color additives, “do not need FDA premarket approval” (FDA, 2025). Products meant to treat or prevent disease are drugs (FDA, 2024).

Congress enacted the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022 (FDA, 2026). It requires facility registration, product listing, serious adverse event reports within 15 business days, and safety records (FDA MoCRA page).

In research, nonapeptide-1 began as a tool compound for studying the α-MSH receptor. It now also appears as a targeting or active part in pigment-related formulation studies, as in the Huang work.

Frequently asked questions about nonapeptide-1

Is nonapeptide-1 a peptide?

Yes. It is nine amino acids joined by peptide bonds, two of them in the D form, with an amide end.

How is nonapeptide-1 related to α-MSH?

It is a modified copy of α-MSH positions 5 to 13. In a 1994 cell screen, it blocked the α-MSH receptor instead of activating it.

Is nonapeptide-1 the same as Melanostatine 5?

PubChem lists Melanostatine 5 as a synonym. We could not confirm the trade name from a manufacturer source.

Is nonapeptide-1 FDA-approved?

No. It is a cosmetic ingredient. US cosmetic ingredients, other than color additives, do not need FDA premarket approval.

Has nonapeptide-1 been tested alone in people?

Not in any peer-reviewed study we found. The one human trial tested a multi-ingredient product.

What to know now

  • Identity: Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2; α-MSH (5-13) analog; 1,206.5 g/mol.
  • Mechanism: α-MSH receptor antagonist in a 1994 cell screen, IC50 11 nM.
  • CosIng functions: hair conditioning and skin conditioning.
  • Evidence: one cell and animal formulation study; one 46-person pilot trial of a mixture, not significant versus sunscreen.
  • Safety: no CIR or SCCS assessment found.
  • Status: cosmetic ingredient; not an FDA-approved drug.

What we’re watching

FDA’s ongoing MoCRA rollout, tracked on its MoCRA page. Any CIR review of nonapeptide-1, which would appear on cir-safety.org. Related guides: afamelanotide, oligopeptide-1 and acetyl tetrapeptide-5.

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: European Commission 2026, CosIng: NONAPEPTIDE-1; National Center for Biotechnology Information 2026, PubChem compound summary for CID 10418849, nonapeptide-1; Jayawickreme 1994, Journal of Biological Chemistry, 269; Huang 2024, International Journal of Pharmaceutics, 665; Chatterjee 2021, Indian Journal of Dermatology, Venereology and Leprology, 88; Bjerke 2026, Current Research in Toxicology, 10; Cosmetic Ingredient Review 2020, Quick reference table; U.S. Food and Drug Administration 2025, FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated; U.S. Food and Drug Administration 2024, Is it a cosmetic, a drug, or both? (Or is it soap?); U.S. Food and Drug Administration 2026, Modernization of Cosmetics Regulation Act of 2022 (MoCRA); Kozlowski 2026, How FDA is implementing landmark cosmetics legislation to positively impact public health. All 11 citations

Back to the research library

References

  1. European Commission. (2026). CosIng: NONAPEPTIDE-1 (substance ID 57418). Retrieved November 17, 2026, from https://ec.europa.eu/growth/tools-databases/cosing/details/57418
  2. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 10418849, nonapeptide-1. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/10418849
  3. Jayawickreme, C. K., Quillan, J. M., Graminski, G. F., & Lerner, M. R. (1994). Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists. Journal of Biological Chemistry, 269(47), 29846-29854. https://doi.org/10.1016/s0021-9258(18)43958-0
  4. Huang, Z. J., et al. (2024). Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging. International Journal of Pharmaceutics, 665, 124690. https://doi.org/10.1016/j.ijpharm.2024.124690
  5. Chatterjee, M., Neema, S., & Rajput, G. R. (2021). A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance. Indian Journal of Dermatology, Venereology and Leprology, 88(1), 51-58. https://doi.org/10.25259/IJDVL_976_18
  6. Bjerke, D. L., et al. (2026). A framework for the safety evaluation of peptides in cosmetics. Current Research in Toxicology, 10, 100291. https://doi.org/10.1016/j.crtox.2026.100291
  7. Cosmetic Ingredient Review. (2020). Quick reference table (September 2020). Retrieved November 17, 2026, from https://www.cir-safety.org/sites/default/files/qrt-fix_0.pdf
  8. U.S. Food and Drug Administration. (2025). FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated (content current as of 11/18/2025). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  9. U.S. Food and Drug Administration. (2024). Is it a cosmetic, a drug, or both? (Or is it soap?) (content current as of 09/11/2024). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  10. U.S. Food and Drug Administration. (2026). Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (content current as of 10/29/2026). Retrieved November 17, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
  11. Kozlowski, S. (2026). How FDA is implementing landmark cosmetics legislation to positively impact public health (FDA Voices; content current as of 05/04/2026). U.S. Food and Drug Administration. https://www.fda.gov/news-events/fda-voices/how-fda-implementing-landmark-cosmetics-legislation-positively-impact-public-health